231 related articles for article (PubMed ID: 15079008)
1. The effect of cannabis on tremor in patients with multiple sclerosis.
Fox P; Bain PG; Glickman S; Carroll C; Zajicek J
Neurology; 2004 Apr; 62(7):1105-9. PubMed ID: 15079008
[TBL] [Abstract][Full Text] [Related]
2. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Wade DT; Makela P; Robson P; House H; Bateman C
Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
Van Der Walt A; Sung S; Spelman T; Marriott M; Kolbe S; Mitchell P; Evans A; Butzkueven H
Neurology; 2012 Jul; 79(1):92-9. PubMed ID: 22753445
[TBL] [Abstract][Full Text] [Related]
4. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis.
Feys P; D'hooghe MB; Nagels G; Helsen WF
Mult Scler; 2009 Mar; 15(3):371-8. PubMed ID: 19168602
[TBL] [Abstract][Full Text] [Related]
5. Sensory dynamic orthoses in mild to moderate upper limb tremor in multiple sclerosis: a mixed methods feasibility study.
Miller L; van Wijck F; Lamont L; Preston J; Hair M
Clin Rehabil; 2016 Nov; 30(11):1060-1073. PubMed ID: 26396165
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Killestein J; Hoogervorst EL; Reif M; Kalkers NF; Van Loenen AC; Staats PG; Gorter RW; Uitdehaag BM; Polman CH
Neurology; 2002 May; 58(9):1404-7. PubMed ID: 12011290
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
[TBL] [Abstract][Full Text] [Related]
8. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.
Carroll CB; Bain PG; Teare L; Liu X; Joint C; Wroath C; Parkin SG; Fox P; Wright D; Hobart J; Zajicek JP
Neurology; 2004 Oct; 63(7):1245-50. PubMed ID: 15477546
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.
Zajicek JP; Sanders HP; Wright DE; Vickery PJ; Ingram WM; Reilly SM; Nunn AJ; Teare LJ; Fox PJ; Thompson AJ
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1664-9. PubMed ID: 16291891
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
Zajicek JP; Hobart JC; Slade A; Barnes D; Mattison PG;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1125-32. PubMed ID: 22791906
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: a prospective case-controlled study.
Alusi SH; Aziz TZ; Glickman S; Jahanshahi M; Stein JF; Bain PG
Brain; 2001 Aug; 124(Pt 8):1576-89. PubMed ID: 11459749
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Collin C; Davies P; Mutiboko IK; Ratcliffe S;
Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
[TBL] [Abstract][Full Text] [Related]
13. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
[TBL] [Abstract][Full Text] [Related]
14. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales.
Tang CC; Soh SE; Boonstra F; Noffs G; Kolbe SC; Butzkueven H; Evans A; Van der Walt A
Mult Scler Relat Disord; 2022 Feb; 58():103495. PubMed ID: 35085981
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of three different ways of assessing tremor in multiple sclerosis.
Alusi SH; Worthington J; Glickman S; Findley LJ; Bain PG
J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):756-60. PubMed ID: 10811700
[TBL] [Abstract][Full Text] [Related]
17. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
18. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].
Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M
Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor.
Jankovic J; Schwartz K; Clemence W; Aswad A; Mordaunt J
Mov Disord; 1996 May; 11(3):250-6. PubMed ID: 8723140
[TBL] [Abstract][Full Text] [Related]
20. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials.
Connor GS; Edwards K; Tarsy D
Clin Neuropharmacol; 2008; 31(2):97-103. PubMed ID: 18382182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
